Table 2. Correlation of RBM3 expression with clinicopathologic characteristics of invasive breast carcinomas.
| Characteristic | RBM3 expression | p-value | |
|---|---|---|---|
| Low expression No. (%) | High expression No. (%) | ||
| Age (yr)* | 49 (24–84) | 50 (26–80) | 0.723 |
| T stage | < 0.001 | ||
| T1 | 28 (7.8) | 115 (31.9) | |
| T2 | 81 (22.4) | 113 (31.3) | |
| T3 | 10 (2.8) | 11 (3.0) | |
| T4 | 2 (0.6) | 1 (0.3) | |
| N stage | 0.004 | ||
| N0 | 50 (13.9) | 131 (36.3) | |
| N1 | 33 (9.1) | 58 (16.1) | |
| N2 | 18 (5.0) | 33 (9.1) | |
| N3 | 20 (5.5) | 18 (5.0) | |
| Histologic grade | < 0.001 | ||
| 1 | 5 (1.4) | 30 (8.3) | |
| 2 | 24 (6.6) | 80 (22.2) | |
| 3 | 92 (25.5) | 130 (36.0) | |
| Estrogen receptor | < 0.001 | ||
| Positive | 52 (14.4) | 194 (53.7) | |
| Negative | 69 (19.1) | 46 (12.7) | |
| Progesterone receptor | < 0.001 | ||
| Positive | 64 (17.7) | 196 (54.3) | |
| Negative | 57 (15.8) | 44 (12.2) | |
| Hormone receptor | < 0.001 | ||
| Positive | 70 (19.4) | 207 (57.3) | |
| Negative | 51 (14.1) | 33 (9.1) | |
| HER2 status | 0.028 | ||
| Positive | 32 (8.9) | 40 (11.1) | |
| Negative | 89 (24.7) | 200 (55.4) | |
| Ki-67 (%) | 0.004 | ||
| < 14 | 36 (10.0) | 109 (30.2) | |
| ≥ 14 | 85 (23.5) | 131 (36.3) | |
| Intrinsic subtype | < 0.001 | ||
| Luminal A | 22 (6.1) | 98 (27.1) | |
| Luminal B, HER2(–) | 29 (8.0) | 84 (23.3) | |
| Luminal B, HER2(+) | 19 (5.3) | 26 (7.2) | |
| HER2-enriched | 15 (4.2) | 13 (3.6) | |
| Triple-negative | 36 (10.0) | 19 (5.3) | |
| Adjuvant chemotherapy | 0.001 | ||
| Yes | 103 (28.5) | 169 (46.9) | |
| No | 18 (5.0) | 71 (19.7) | |
| Adjuvant radiotherapy | 0.600 | ||
| Yes | 52 (14.4) | 112 (31.0) | |
| No | 69 (19.1) | 128 (35.5) | |
RBM3=RNA-binding motif protein 3; HER2=human epidermal growth factor receptor 2.
*Median (range).